Nuclear Medicine Market Size 2025: Global Share, Industry And Report Analysis by 2030
Nuclear Medicine Market Overview:
The global nuclear
medicine market is expected to grow at a compound annual growth rate
(CAGR) of 12% over the forecast period. Key drivers include the rising
prevalence of cancer and cardiovascular diseases, increased use of hybrid
imaging systems, innovations in radiopharmaceuticals, and growing government
investment in nuclear medicine research. However, challenges such as high
equipment and radiopharmaceutical costs, regulatory complexities, and the
limited availability of radioisotopes could impede market expansion.
Download Sample Copy: https://meditechinsights.com/global-nuclear-medicine-market/request-sample/
Nuclear medicine encompasses advanced diagnostic and
therapeutic techniques that use radioactive substances to diagnose and treat a
wide range of medical conditions. At the heart of these methods are
radiopharmaceuticals and molecular imaging technologies, which offer detailed
insights into physiological processes and enable targeted, effective
treatments. Primarily used in oncology, cardiology, and neurology, nuclear
medicine provides non-invasive options for early disease detection and
treatment.
Increasing Burden of Cancer and
Cardiovascular Diseases
The growing global prevalence of cancer and
cardiovascular diseases is a major driver for the expansion of the nuclear
medicine market. These conditions require precise diagnostic methods and
effective therapies—both of which nuclear medicine can provide. With its
ability to detect cellular-level changes and deliver targeted radiation
therapy, nuclear medicine plays a critical role in early diagnosis and
treatment. According to the World Health Organization (WHO), cardiovascular
diseases are the leading cause of death worldwide, responsible for an estimated
17.9 million deaths annually as of 2019. Likewise, the International Agency for
Research on Cancer (IARC) reported nearly 20 million new cancer cases in 2022,
along with 9.7 million cancer-related deaths. Nuclear imaging technologies like
PET and SPECT are essential for the early detection, staging, and monitoring of
these diseases, while radiopharmaceutical therapies, such as theranostics,
provide personalized treatment options that improve patient outcomes. As
awareness of these benefits grows, both healthcare professionals and patients
are increasingly adopting nuclear medicine for better diagnosis and treatment
of these life-threatening conditions.
Download Sample Copy: https://meditechinsights.com/global-nuclear-medicine-market/request-sample/
Innovations in Radiopharmaceuticals:
Advancing Diagnostics and Treatment
Next-generation radiopharmaceuticals are
revolutionizing nuclear medicine, expanding its capabilities in both
diagnostics and therapeutic treatments. New isotopes, such as Lutetium-177 and
Actinium-225, are being developed for targeted radioligand therapy, offering
highly specific cancer treatments with minimal damage to healthy tissues. On
the diagnostic side, innovations like fluorine-based tracers and other advanced
molecules are enhancing imaging techniques for complex conditions such as
Alzheimer's disease and neuroendocrine tumors. Strong collaboration between
pharmaceutical companies and academic institutions, along with substantial
research investments, is driving these innovations. By addressing the
limitations of current isotopes and broadening therapeutic applications, these
next-generation radiopharmaceuticals are making nuclear medicine more effective
and accessible. As a result, personalized treatment approaches are becoming
more common, leading to improved patient outcomes and accelerating market
growth.
Market Segmentation
This report by Medi-Tech Insights provides the size
of the nuclear medicine market at the regional- and country-level from
2023 to 2030. The report further segments the market based on product,
application and end-user.
·
Market Size
& Forecast (2023-2030), By Product, USD Million
o Diagnostics
§ SPECT
o TC-99m
o TL-201
o GA-67
o I-123
o Others
§ PET
o F-18
o SR-82/RB-82
o PYLARIFY (piflufolastat F 18)
o Illuccix (gallium Ga 68 gozetotide)
o Others
o Therapeutics
§ Alpha Emitters
o RA-223
o Others
§ Beta Emitters
o I-131
o Y-90
o SM-153
o Re-186
o Lu-177
o Others
§ Brachytherapy
o Cesium-131
o Iodine-125
o Palladium-103
o Iridium-192
o Others
·
Market Size
& Forecast (2023-2030), By Application, USD Million
o Cardiology
o Neurology
o Oncology
o Thyroid
o Lymphoma
o Bone Metastasis
o Endocrine Tumor
o Pulmonary Scans
o Urology
o Other
·
Market Size
& Forecast (2023-2030), By End-user, USD Million
o Hospitals
o Diagnostic Centers
o Others
·
Market Size
& Forecast (2023-2030), By Region, USD Million
o North America
§ US
§ Canada
o Europe
§ UK
§ Germany
§ Italy
§ Spain
§ Rest of Europe
o Asia Pacific
§ China
§ India
§ Japan
§ Rest of Asia Pacific
o Latin America
o Middle East & Africa
Browse Report: https://meditechinsights.com/global-nuclear-medicine-market/
About Medi-Tech Insights ;
Medi-Tech Insights is a healthcare-focused business research &
insights firm. Our clients include Fortune 500 companies, blue-chip investors
& hyper-growth start-ups. We have completed 100+ projects in Digital Health,
Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the
areas of market assessments, due diligence, competitive intelligence, market
sizing and forecasting, pricing analysis & go-to-market strategy. Our
methodology includes rigorous secondary research combined with deep-dive
interviews with industry-leading CXO, VPs, and key demand/supply side
decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
Comments
Post a Comment